Kornitzer Capital Management Inc. KS Has $4.99 Million Stock Holdings in HealthEquity, Inc. (NASDAQ:HQY)

Kornitzer Capital Management Inc. KS lowered its position in HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 71.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 75,326 shares of the company's stock after selling 188,492 shares during the quarter. Kornitzer Capital Management Inc. KS owned approximately 0.09% of HealthEquity worth $4,994,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. McGlone Suttner Wealth Management Inc. bought a new position in HealthEquity during the fourth quarter valued at about $29,000. Castleview Partners LLC bought a new position in HealthEquity during the second quarter valued at about $39,000. Lazard Asset Management LLC grew its holdings in HealthEquity by 117.9% during the third quarter. Lazard Asset Management LLC now owns 549 shares of the company's stock valued at $40,000 after purchasing an additional 297 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new position in HealthEquity during the third quarter valued at approximately $41,000. Finally, Fifth Third Bancorp grew its holdings in HealthEquity by 36.5% during the third quarter. Fifth Third Bancorp now owns 602 shares of the company's stock valued at $44,000 after purchasing an additional 161 shares during the last quarter. 99.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at HealthEquity

In related news, Director Evelyn S. Dilsaver sold 32,500 shares of the business's stock in a transaction on Tuesday, March 26th. The stock was sold at an average price of $79.29, for a total value of $2,576,925.00. Following the sale, the director now owns 32,123 shares of the company's stock, valued at approximately $2,547,032.67. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, Director Evelyn S. Dilsaver sold 32,500 shares of HealthEquity stock in a transaction dated Tuesday, March 26th. The shares were sold at an average price of $79.29, for a total transaction of $2,576,925.00. Following the completion of the transaction, the director now directly owns 32,123 shares of the company's stock, valued at approximately $2,547,032.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Delano Ladd sold 2,558 shares of HealthEquity stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $82.59, for a total transaction of $211,265.22. Following the transaction, the executive vice president now directly owns 47,438 shares of the company's stock, valued at $3,917,904.42. The disclosure for this sale can be found here. Insiders have sold a total of 71,322 shares of company stock valued at $5,682,895 over the last quarter. 2.70% of the stock is owned by company insiders.

HealthEquity Stock Performance

HQY traded up $1.04 during trading on Friday, reaching $80.89. 556,190 shares of the company's stock were exchanged, compared to its average volume of 558,683. HealthEquity, Inc. has a fifty-two week low of $48.86 and a fifty-two week high of $84.49. The company has a market capitalization of $6.94 billion, a P/E ratio of 126.39, a PEG ratio of 1.32 and a beta of 0.53. The company has a quick ratio of 4.76, a current ratio of 4.76 and a debt-to-equity ratio of 0.43. The business has a 50 day moving average price of $81.08 and a 200 day moving average price of $74.28.

HealthEquity (NASDAQ:HQY - Get Free Report) last posted its earnings results on Tuesday, March 19th. The company reported $0.50 earnings per share for the quarter, beating analysts' consensus estimates of $0.42 by $0.08. The business had revenue of $262.39 million for the quarter, compared to analysts' expectations of $258.56 million. HealthEquity had a net margin of 5.57% and a return on equity of 6.91%. As a group, analysts predict that HealthEquity, Inc. will post 2.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on HQY. BTIG Research increased their price target on HealthEquity from $100.00 to $110.00 and gave the company a "buy" rating in a report on Wednesday, March 20th. Bank of America upped their price target on shares of HealthEquity from $93.00 to $97.00 and gave the company a "buy" rating in a report on Wednesday, March 20th. Barclays upped their price target on shares of HealthEquity from $84.00 to $104.00 and gave the company an "overweight" rating in a report on Friday, February 23rd. JPMorgan Chase & Co. upped their price target on shares of HealthEquity from $86.00 to $108.00 and gave the company an "overweight" rating in a report on Tuesday, April 2nd. Finally, Royal Bank of Canada upped their price target on shares of HealthEquity from $90.00 to $92.00 and gave the company an "outperform" rating in a report on Wednesday, March 20th. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $96.17.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.